Related Experiment Video

Updated: Sep 25, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors

    Cancer Discovery
    |May 2, 2022
    PubMed

    Insights

    Resistance to noncovalent Bruton's tyrosine kinase (BTK) inhibitors can occur due to mutations in BTK or PLCγ2. These genetic alterations, specifically non-C481 BTK mutations, are key mechanisms driving treatment failure.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Bruton's tyrosine kinase (BTK) inhibitors are crucial in treating B-cell malignancies.
    • Noncovalent BTK inhibitors offer a therapeutic option but can face resistance.
    • Understanding resistance mechanisms is vital for improving treatment strategies.

    Purpose of the Study:

    • To investigate the genetic mutations responsible for resistance to noncovalent BTK inhibitors.
    • To identify specific alterations in BTK and downstream signaling pathways that confer resistance.

    Main Methods:

    • Analysis of patient samples with acquired resistance to noncovalent BTK inhibitors.
    • Genomic sequencing to identify mutations in BTK and PLCγ2.
    • Functional assays to assess the impact of mutations on BTK activity and signaling.

    Main Results:

    • Acquired resistance is frequently mediated by mutations in BTK at residue C481 or other sites.
    • Mutations in Phospholipase C gamma 2 (PLCγ2) are also identified as a significant resistance mechanism.
    • These mutations lead to altered BTK signaling and reduced drug efficacy.

    Conclusions:

    • Non-C481 BTK mutations and PLCγ2 mutations are primary drivers of resistance to noncovalent BTK inhibitors.
    • Targeting these specific mutations may offer strategies to overcome treatment resistance in B-cell cancers.

    More Related Videos

    Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

    Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

    Published on: October 23, 2019

    8.0K
    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

    Published on: January 7, 2019

    8.4K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.9K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.4K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    4.1K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.9K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.1K
    Cytotoxic T Cells-mediated Immune Response01:27

    Cytotoxic T Cells-mediated Immune Response

    Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
    Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
    2.8K